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0. Executive summary 
 
This report presents a picture of European opinion on farm animal cloning. In this report, as 
in the other publications arising from the project Cloning in Public, both agricultural and 
biomedical applications of farm animal cloning are considered. With the arrival of Dolly, 
animal cloning became an integral part of the biotech debate, but this debate did not isolate 
animal cloning as a single issue. 
 
The report suggests that two scales are important in European attitudes to animal cloning. 
The first is scale of the organism: animal cloning address higher organisms, it evokes thus 
more concern. The second is the scale of application: medical applications generally are re-
garded as more acceptable than food applications. These scales suggest that farm animal 
cloning in the food area will be regarded with deep scepticism by the public, while applica-
tions with a medical purpose will be regarded as more acceptable, depending among other 
things on the purpose and the animals involved. 
 
However, it should be borne in mind that our existing knowledge of European perceptions of 
farm animal cloning is somewhat limited owing to a lack of qualitative and quantitative stud-
ies focusing on this specific issue. 
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1. Introduction 
 
This report is the fourth deliverable from the project “CLONING IN PUBLIC”; a specific sup-
port action within the sixth framework programme, Priority 5, Food quality and safety” (Con-
tract no. 514059).  
 
The report presents a picture of European opinion on farm animal cloning. The report reviews 
existing quantitative and qualitative studies of public perceptions of biotechnology. It looks at 
the few studies covering farm animal cloning, and places them within the context of animal 
biotechnology. Eurobarometer surveys are by far and away the most important source of 
quantitative data on public perceptions of biotechnology in Europe. 
 
In the report, the term “farm animal” refers to farm animal species such as ruminants (e.g. 
cows, sheep), pigs and poultry (chicken, turkey). The term does not imply in every case that 
the animal is kept or used in an agricultural setting or for agricultural purposes. Thus, the 
potential use of a cloned farm animal species may be in medicine (see: Danish Centre for 
Bioethics and Risk Assessment (CeBRA) (2005)).  
 
This report forms the basis of a second ethical report containing an assessment of attitudes 
and concerns affecting perceptions of risk, benefit, and moral acceptability, and an examina-
tion of ways to balance these concerns, and to describe the values that underlie them. The 
second ethical report will analyse and discuss concerns relating to human health and the envi-
ronment, animal welfare problems, animal integrity, and the relationship between science, 
technology, commercial interests and society in the light of the perceived usefulness of farm 
animal cloning. 
 
CLONING IN PUBLIC materials on the scientific, legal and ethical aspects of farm animal 
cloning are publicly available. All project reports, as well a list of the project’s deliverables, 
presentations, work plans and workshops are available at the project website: 
www.bioethics.kvl.dk/cloninginpublic.htm
 
The main objectives of CLONING IN PUBLIC are: (a) to develop recommendations on the 
preparation of European regulation of, and guidelines covering, research on farm animal clon-
ing and its subsequent applications (e.g. in genetically modified animals for bio-reactors); and 
(b) to stimulate informed public debate across Europe on these issues involving key stake-
holders, university students and members of the public. These two aims are of equal impor-
tance. They are also interrelated, because if regulations and guidelines are to serve their pur-
pose, they must take public concerns into account. In addition, stimulating, informing and re-
porting public debate is part of the more general, long-term aim of improving communication 
between science, civil society and European authorities at different levels, and hence facilitat-
ing discussion of European public affairs connected with science and technology. 
 
This report has been prepared by Dr. Jesper Lassen, Department of Human Nutrition/the Dan-
ish Centre for Bioethics and Risk Assessment (CeBRA) at the Royal Veterinary and Agricul-
tural University, Copenhagen, Denmark. 
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2. Public debate about animal biotechnology 
 
It is fair to say that the development and use of (farm) animal cloning was a minor issue on 
the public biotechnology agenda until the mid-1990s. Previously the focus in the public de-
bate, as reflected in the media, was on micro organisms, plants and to lesser extent transgenic 
animals. (For an overview of the debate in Europe, see Gaskell and Bauer, 2005; Durant et 
al., 1998.) From a strictly technical point of view, the relative absence of animal cloning as 
an issue is somewhat surprising, since cloning and other new biotechnologies, such as trans-
genic animals, are interconnected technologies, and since cloning can in some cases be a 
helpful tool in producing genetically modified animals. 
 
This picture changed, however, dramatically and almost overnight, in 1997, as the birth of the 
cloned Dorset ewe Dolly was announced. As has been noticed, a number of cloning experi-
ments had taken place in the years preceding Dolly’s arrival; none of these, however, made 
their way into the media spotlight on a scale comparable with Dolly (Einsiedel et al. 2002).1 
What helped to make Dolly breaking news – and the first global biotechnology event ever – 
was the fact that she was the first result of somatic cloning: that is, she was produced from a 
body cell from an adult sheep, and not, as earlier animal clones had been, on embryos or em-
bryonic cells. 
 
Dolly not only marked a scientific breakthrough, but provided a straightforward link to exist-
ing (popular) discourses about human cloning and thus ensured that animal cloning was an 
integral part of the biotechnology debate. This debate has, like most debates, not isolated 
animal cloning as a single issue, but discussed it within various contexts and with reference 
to a variety of other debates – including human cloning, therapeutic cloning, transgenic ani-
mals, research animals and xenotransplantation. The following chapter aims to present a pic-
ture of European opinion on farm animal cloning. 
 
                                                 
1 See also the first Technical Report from the CLONING IN PUBLIC project: The science and technology of 
farm animal cloning available at http://www.sl.kvl.dk/cloninginpublic/ 
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3. Public opinion on farm animal cloning in Europe: 
sources of information. 
 
An initial search for studies of public perceptions of farm animal cloning in bibliography 
databases revealed that this issue has rarely been the main focus of studies of public opinion. 
Instead, farm animal cloning has occasionally been included as one aspect in broader studies 
of perceptions of biotechnology in general. Knowledge about public perceptions in this area 
also varies both geographically, since the number of studies differs from country to country, 
and historically, since the studies do not cover the development of opinions over lengthy pe-
riods of time. 
 
Given the limited published research, a review of public opinion confined to the targeted 
studies would be imperfect in many ways. However, broadening the scope to include other 
animal-related applications of biotechnology will not only help fill in the knowledge gaps, 
but also provide a helpful, context in which to understand concerns about farm animal clon-
ing. Thus this report will examine the small number of studies of farm animal cloning, and 
place them within the context of animal biotechnology. The sources of scientifically reliable 
information about public opinion on animal biotechnology can be divided into qualitative and 
quantitative studies. 
 
This approach will also help with another problem with any attempt to uncover public per-
ceptions of animal cloning: namely, that cloning always exists in a context. Animal cloning 
is, by and large, a ‘stand-alone’ technology only at the basic research level, where the focus is 
on developing the technique itself. In most other arenas, animal cloning operates within the 
context of its application. Potential applications are reportedly in food production, molecular 
pharming, xenotransplantation, the pet sector, sporting animals, protection of endangered 
species and so on. For an assessment of the relevance of farm animal cloning to these appli-
cations, see Danish Centre for Bioethics and Risk Assessment (CeBRA) (2005). In any at-
tempt to uncover public perceptions of animal cloning, the problem often is that these other 
areas of biotechnology, such as laboratory animals, transgenic animals or xenotransplantation 
are themselves are controversial. It can be extremely hard to say to what extent this affects 
the perception of cloning. 
 
Our knowledge of public perceptions derives from two different types of study. Quantitative 
studies, such as surveys, display data on the distribution of perceptions in a population based 
on representative samples. In addition, quantitative studies can – when the same design is 
repeated over the years – describe developments in opinion. While the strength of quantita-
tive studies lies in their ability to characterise opinions in a population, and to show how 
opinions about different issues relate to each other or to demographic characteristics, their 
weakness lies in their inability to account for in-depth knowledge of the arguments behind 
the different opinions. 
 
Eurobarometer surveys are by far and away the most important source of quantitative infor-
mation on public perceptions of biotechnology in Europe. Since 1989 these surveys have 
been carried out within the frameworks set by the EU Commission at three year intervals. 
The most recent survey was conducted in 2002. The surveys cover a population of 1000 per-
sons in each EU country. Since 1996 a number of non-EU countries have been included. The 
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Eurobarometers have, over time, incorporated various questions addressing issues related to 
animal biotechnology. However, few of these questions is included in more than one Euro-
barometer, so the surveys cannot be used to describe developments in attitude over the rele-
vant years. In addition to the Eurobarometer surveys, a number of national surveys have been 
carried out in EU member states. The quantitative data drawn upon in the following review 
will, however, chiefly is drawn from Eurobarometers. 
 
Secondly, qualitative studies complement quantitative studies by offering in-depth informa-
tion about the nature of public opinion – e.g. information about prominent kinds of argumen-
tation and discourse. The methods used in these studies are different forms of interview. Of-
ten focus groups are set up, where a small group of interviewees (most often 6-10) is guided 
through a structured discussion. Due to the relatively small population of respondents in 
qualitative studies, such studies suffer from a lack of statistical representativity. Hence a 
combination of qualitative and quantitative data will often provide the best picture of public 
opinion. 
 
Most qualitative studies of public perceptions of biotechnology cover only one or a few coun-
tries. A few studies do, however, include four or more countries. One study covers 10 Euro-
pean countries, and was carried out as a follow-up study to the 1999 Eurobarometer (Gaskell 
and Bauer, 2005). Another includes five European countries (Marris et al. 2001). The qualita-
tive side of the following review will be based on these later studies as well other studies 
conducted in single countries. 
 
The reader is reminded that the differing nature of the knowledge produced by different 
methods means that, while survey results sometimes appear homogeneous across countries 
(e.g. the majority of lay people in most countries are sceptical about GM foods), qualitative 
studies may reveal that the thinking, or argumentation, behind this scepticism depends very 
much on the national or local context – as it has been suggested in relation to national debates 
following the arrival of GM soy in Europe in 1996 (Lassen et al. 2002a). Hence the findings 
of qualitative studies may be difficult to generalise from country to country, despite appar-
ently similar quantitative profiles. 
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4. Europeans and farm animal cloning 
 
Although there is no simple solution to the problem that cloning always operates in a context, 
the few studies that explicitly cover animal cloning tend to connect animal cloning with its 
outcomes and isolate it from associated technologies. This happened in the 1999 Euro-
barometer, in which a battery of questions was designed to uncover perceptions of different 
applications. One of the applications to be considered was “Cloning animals such as sheep to 
get milk which can be used to make medicines and vaccines”. Here the outcome/ product 
(milk with medicine/ vaccines) is included, but it is not mentioned that this outcome also de-
pends on the development of transgenic sheep. 
 
Such questions, comparing different biotechnologies, have been included in all Eurobarome-
ters since 1996. The choice of applications asked about varies, however, from survey to sur-
vey (see Table 1). In this battery of questions the respondents are asked to state to what ex-
tent they found the different applications useful for society; risky for society; and morally 
acceptable; and to what extent the applications should be encouraged. Despite the variation in 
the included applications, the questions offer an opportunity to characterise the judgement of 
different types of biotechnology over time. Furthermore, since different applications involv-
ing animals are included in all three surveys, the surveys enable some of animal-related ap-
plications to be compared. 
 
Table 1 shows the extent to which different applications should be encouraged according to 
the Eurobarometers in 1996, 1999 and 2002. If the desire to encourage is taken as an indica-
tion of the level of support of the different applications, some general conclusions can be 
drawn. It emerges, secondly, in Table 1 that some medical applications score low or very low 
on the support scale. It is characteristic that these applications (items 6, 7 and 9) are the only 
medical applications that also involve animals, whereas the others (to the extent that they 
mention the manipulated object) involve plants, micro organisms and even human cells. This 
seems to indicate that the mere involvement of animals makes an application questionable, 
despite the fact that it belongs to the generally approved medical area. 
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Table 1. Mean scores in the judgement of the extent to which different applications of bio-
technology should be encouraged in the 15 EU countries. 
 
 
“Should be encouraged” 
Mean score in 15 EU countries 
-2= negative +2=positive attitude 
 
Now let's talk about using modern biotechnology in the production of foods, 
for example to make them higher in protein, keep longer or change the taste. 
From now on I am going to call this GM food, that is genetically modified 
food. Please tell me whether you strongly agree, somewhat agree, neither 
agree nor disagree, somewhat disagree or strongly disagree with each of the 
following statements? 
2002 a) 1999 b) 1996 c) 
 
1 
Using genetic testing to detect diseases we might have inherited from our 
parents such as cystic fibrosis, mucoviscidosis or thalassaemia  0,69 0,67 0,91 
 
2 
Introducing human genes into bacteria to produce medicines or vaccines, for 
example to produce insulin for diabetics na 0,51 0,81 
3 Developing genetically modified bacteria to clean up slicks of oil or danger-ous chemicals na 0,51 na 
 
4 
Cloning human cells or tissues to replace a patient’s diseased cells that are 
not functioning properly, for example, in Parkinson's disease or forms of 
diabetes or heart disease 
0,49 0,33 na 
 
5 
Using genetically modified organisms to produce enzymes as additives to 
soaps and detergents that are less damaging to the environment 0,23 na na 
6 Developing genetically modified animals for laboratory research studies, such as a mouse with genes that cause it to develop cancer na na 0,22 
7 Introducing human genes into animals to produce organs for human trans-plants, such as into pigs for human heart transplants 0,13 na -0,22 
8 Taking genes from plant species and transferring them into crop plants, to make them more resistant to insect pests 0,08 0,03 0,34 
9 Cloning animals such as sheep to get milk which can be used to make medi-cines and vaccines na -0,17 na 
10 Use modern biotechnology in the production of foods, for example to make them higher in protein, keep longer or improve the taste -0,26 -0,31 -0,11 
 
REFERENCES: a) European Commission (2002) Eurobarometer 58.0 (The data set). ; b) 
INRA (Europe) (2000) Eurobarometre 52.1. (The data set) c) Durant, J., Bauer, M.W. & 
Gaskell, G. (eds.) (1998): Biotechnology in the public sphere – a European sourcebook. Sci-
ence Museum. London. 
NOTE: “na” in the table indicates that this question was not included in this Eurobarometer. 
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Similar findings have been made in quantitative studies in Spain and the US. These findings 
show  a scale of acceptability with manipulation of plants as the most acceptable, followed by 
bacteria, animals, human somatic cells and human embryos as the least acceptable (Lujan and 
Moreno 1994). The notion that transgenic animals evoke particular unease is supported in 
qualitative studies carried out in the UK (Macnaghten 2001), where focus group participants, 
with few exceptions, reacted negatively to a list of applications involving transgenic ani-
mals.2 The negative reaction here was found to be based on arguments about issues such as 
unnaturalness; need/usefulness; unforeseen effects; and lack of respect for nature. A psycho-
metric study of perceptions of gene technology on plants, animals and humans in Japan 
showed the same pattern (Tanaka 2004). 
 
Returning to the Eurobarometer data, it should be noted that the only animal application ex-
plicitly mentioning cloning (item 9 in table 1: Cloning animals such as sheep to get milk 
which can be used to make medicines and vaccines) is the second least supported application 
– surpassed only by GM foods. This seems to indicate that cloning is a particularly contro-
versial technology. However, the scepticism may reflect not only the above-mentioned ‘ani-
mal-factor’, but also the historical context of the late 1990s. Hence there is a clear resem-
blance between the application asked about and the, at that time, well known and in many 
countries alarming, arrival of Dolly the sheep. The low score may thus partly reflect gener-
ally negative discourse about Dolly in particular and cloning in general that prevailed in 
many EU countries in the late 1990s. 
 
Thirdly, statistical analysis of the relation between the desire to encourage an application and 
its perceived risk, usefulness and moral acceptability, show that moral assessment is the most 
important factor behind the level of support. This was interpreted as a moral veto: “First use-
fulness is a precondition of support; second, people seem prepared to accept some risk as 
long as there is a perception of usefulness and no moral concern; but third and crucially, 
moral doubts act as a veto irrespective of people’s views on use and risk” (Wagner et al. 
1997). Although the analysis of Eurobarometers suggests the existence of a moral veto, the 
Eurobarometers offer little help when it comes to breaking down what the respondents actu-
ally mean when they respond to the question whether an application is morally acceptable or 
not. 
 
An indication of some aspects of moral concern and perceived usefulness in relation to ani-
mals emerges from the 1999 survey, which included a series of questions about “cloning 
animals, for instance to get milk which can be used to make medicines and vaccines”. It 
should be noted that, once again, the focus of the Eurobarometer is only on medically related 
cloning, and that farm animal cloning for food purposes is excluded. First of all, the generally 
negative attitude to animal cloning is reconfirmed: almost two in three respondents agree to 
some extent that cloning of animals is a dreadful idea (see Table 2). An analysis of the group 
                                                 
2 The stimuli for this section of the study did not mention animal cloning, but included the following eight ex-
amples: “Cows that produce milk with lower cholesterol and enhanced nutrients. Faster growing farm animals 
and faster growing fish. Farm animals with reduced sentience to make them less distressed by farm conditions. 
Cats that do not cause human allergies. Cats that have their hunting instinct reduced/ removed. Mosquitoes that 
cannot transmit parasitic diseases such as malaria which are breed to replace, at least locally, wild populations. 
Sheep or cows that make pharmaceutical products in their milk. Pigs that are breed to produce organs, such as 
hearts, that can be xenotransplanted into humans.” (Macnaghten 2001) 
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of respondents found to be most supportive of biotechnology revealed that even this group 
was sceptical about the cloning of animals. Thus 64% of the supporters believed that cloning 
threatened the natural order; 72% that even though there are benefits cloning is unnatural; 
and 48% of supporters thought that cloning poses a risk to future generations (Gaskell et al. 
2000). In addition, and not surprisingly, the most recent Eurobarometer on Social Values, 
Science and Technology (European Commission, 2005) shows that support for medical clon-
ing is a little higher among those who believe we have the right to exploit nature; and simi-
larly, a little lower among those who do not agree with this.3 So 36% of those who disagree 
that we have the right to exploit nature also say that we could never allow medical cloning. 
This compares with an EU average of 31%. In all 12% of those who agree that we have the 
right to exploit nature also say that medical cloning is acceptable in all circumstances. This 
compares with an EU average of 8%. 
 
There is little doubt that concerns about unnaturalness are an important aspect of the moral 
category in the Eurobarometers. Indeed a number of qualitative studies have stressed the im-
portance of perceived unnaturalness in trying to understand public concerns (e.g.: Macna-
ghten, 2001; Madsen et al., 2002; Marris et al., 2001; Wagner et al., 2001; Grove-White et 
al., 1997). Modern biotechnology seems to cross an invisible border between natural and 
unnatural. According to some of these studies, it is recognised that, for example, modern 
farming too is unnatural; modern biotechnology, however, adds some qualitatively new fea-
tures, such as crossing barriers between species and speeding up natural processes, that make 
it particularly unnatural. Although none of these qualitative studies explicitly mentions, let 
alone addresses, the cloning of farm animals, it is likely that what makes this technology un-
natural in the eyes of the public is the fact that it bypasses sexual reproduction. 
 
Although animal welfare is generally known to be an issue of importance in many European 
countries, the issue has played a surprisingly limited role in debates about the new biotech-
nologies. These debates have addressed mainly physical harm (e.g. increased occurrence of 
mastitis due to the use of BST) and questions of integrity. Integrity and dignity are important 
components of the morally based rejection of GM animals found in qualitative studies (e.g. 
Lassen et al. 2005; Macnaghten 2001). Concerns in this category include the worry that ge-
netic manipulation deprives animals of intrinsic features and blurs the borderline between 
animals and machines, or between species. According to these studies, it is important to the 
public that genetic technologies do not violate the integrity of the animals. Again, cloning is 
not reported as a single issue, but it is reasonable to assume that, in connection with animal 
cloning, this would translate into a concern about the act of cloning depriving an animal of 
features of its intrinsic character, such as uniqueness.  
 
When it comes to usefulness (items 2 & 3 in table 2), 60% to some extent support the state-
ment that cloning “is simply not necessary”. One explanation of this negative evaluation 
could be a low expectation of benefits to be brought by the technology: thus only 24% be-
lieve to some extent that cloning will bring benefits to a lot of people. This finding is a little 
surprising, since cloning here is talked about as a means of producing medicines and vac-
                                                 
3 The wording of the two claims the respondents were asked to tell to what extent they approved of was: “Clon-
ing animals such as monkeys or pigs for research into human diseases” (options: In all circumstances; Only if it 
is highly regulated; Only in exceptional circumstances; Never) and “ Right to exploit nature for the sake of 
human well-being” (options: Agree; Disagree) 
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cines. When gene technology in general is framed in this way, it is normally associated with 
relatively high levels of perceived usefulness. 
 
The question of perceived usefulness, however, is not a simple one. Qualitative studies have 
suggested that people operate with rather different understandings of usefulness when they 
consider genetic engineering; and furthermore, that the context needs to be taken into consid-
eration. The PABE study (Public Perceptions of Agricultural Biotechnologies in Europe) 
employing focus groups in five countries (I, UK, F, D & E) found that participants distin-
guished between need in medical biotechnology and need in the food area (Marris et al., 
2001). The generally accepted medical applications were talked about as means to solve 
problems where no other available alternatives exist, and thus seen as useful. By contrast GM 
food was not seen as needed because food, in the developed world is available. Furthermore 
there are alternatives to GM foods as a means to alleviate hunger in the third world, namely 
relocation of some the surplus in rich countries. Similarly a study in Denmark (Lassen et al., 
in press; Lassen and Jamison, in press) revealed a distinction between societal usefulness, 
self-interested usefulness (i.e. benefit to the individual) and economic usefulness (i.e. techni-
cal and financial usefulness to business). This study found that GM animals can be legiti-
mised if they fulfil a societal need. However, participants were divided in their understanding 
of societal need: some saw, for example, obesity as a self-inflicted problem and hence not as 
a suitable argument for GM animals (in the presented case GM rats to be used in obesity re-
search). Others argued that obesity is comparable to deceases and/ or presents a societal prob-
lem of a scale making it a good argument in favour of gene technology.  
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Table 2. Judgements about animal cloning in the 15 EU membership countries in 1999. 
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1 I dread the idea of cloning animals 35 26 16 12 7 5 
2 Cloning animals will bring benefits to a lot of people 6 18 19 22 24 11 
3 Cloning animals is simply not necessary 36 24 16 11 4 9 
4 Cloning animals threatens the natural order of things 44 30 11 6 3 6 
5 Even if cloning animals has benefits it is fundamentally unnatural 51 26 9 5 3 6 
6 The risks from cloning animals are acceptable 4 13 16 25 30 12 
7 If anything went wrong with cloning animals, it would be a worldwide catastrophe 33 25 15 11 4 13 
8 Cloning animals poses no danger for future generations 4 9 16 24 31 16 
9 Deciding on the issue of cloning animals is so complex that public con-sultation about it is a waste of time 12 18 16 20 24 10 
10 If the majority of people were in favour of cloning animals, then it should be allowed 7 17 18 22 28 9 
11 Even if it means missing out on some of its benefits, cloning should be introduced more gradually 13 25 19 12 18 12 
12 Whatever the risks from cloning animals, you can avoid them if you really want to 15 22 17 13 14 20 
13 Of all the risks we face these days, the risk from cloning animals is quite small 6 20 20 21 18 14 
 
REFERENCE: INRA (Europe) (2000) Eurobarometre 52.1. (The data set) 
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The relatively low levels of perceived usefulness (Table 2, item 3: “Cloning animals is simply 
not necessary”) found in the Eurobarometer may reflect the fact that animal cloning, although 
presented within the medical area, is not seen as a unique technique, but is rather looked upon 
as an alternative to existing means of medical production.4 Qualitative research here indicates 
that perceived usefulness might have been judged higher if the respondents had been asked 
about medical uses of animal cloning beneficial to the respondents themselves. This might 
have been the case, for example, if the respondent or a close relative the respondent, was se-
riously ill. Such threats might lead people to leave concerns about xenotransplantation behind 
in order to “outwit death” (Sanner 2001). Similarly, the absence of alternatives generally af-
fects judgements about usefulness, as has been confirmed in qualitative studies of xenotrans-
plantation. In 2004, a review of 35 qualitative studies covering 23 countries (Hagelin 2004) 
concluded that if xenotransplantation was the only choice (i.e. only alternative), the propor-
tion of acceptance increased. 
                                                 
4 Note that the wording of the question present cloning neutrally, and not as a unique technology. 
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5. Farm animal cloning and the US public.  
 
The American public has a more positive perception of biotechnology than the European 
public. A survey, conducted by Texas A&M University, which is in many ways equivalent to 
the 1999 Eurobarometer, revealed that some 52% of the US public held the optimistic view 
that genetic engineering “would improve the quality of life” (Eyck et al 2001). The compara-
ble figure for Europe was 41%. These high expectations in the US are confirmed in a time-
series study conducted by International Food Information Council (IFIC 2005). This shows 
that, since 1999, between 59% and 64% were of the opinion that biotechnology would pro-
vide them benefits within a five-year timeframe. It should, however, be noted that these rela-
tively high expectations had decreased from 78% in 1997. 
 
However, the IFIC survey also shows that the US public is somewhat reluctant to use animal 
biotechnology in agriculture: in 2005 27% found it favourable; 32% not favourable; 10% 
neither favourable nor unfavourable; and 30% were not able to form an opinion about the 
issue. This kind of hesitation about animal biotechnology is reflected in US opinion about the 
cloning of animals in general: in 2005 74% found this unfavourable and only 15% found it 
favourable (10% answered “neither nor” and 2% “don’t know”). In a follow-up question, 
respondents were asked how likely they were to buy food products from cloned animals if it 
was determined by the Food and Drug Administration (FDA) that they were safe to eat. Two-
thirds (64%) stated that they were unlikely to buy such products, and just one-third (34%) 
said that they would be likely to do so. These figures seem to mirror the situation in Europe. 
They suggest that that rejection is not based primarily on safety risks. This suggestion re-
ceives support from statistical analysis of the data from the Texas A&M University survey in 
1999. This analysis reveals that in the US moral acceptability is a better predictor of encour-
agement that risk or usefulness (Eyck et al 2001). 
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6. Concluding remarks 
 
In general, it can be concluded that our knowledge of public perceptions of animal cloning is 
surprisingly limited. Going by the debate following the arrival of Dolly, one would have ex-
pected work on society and animal cloning to have a higher position on the research agenda. 
Instead studies of public perceptions of genetic manipulation have generally focused on other 
issues, food issues being dominant. This absence of work on public perception should not 
lead to the misconception that the public is not concerned about these matters. Quite the con-
trary is the case – ordinary people are indeed very concerned about cloning. It is a concern 
that the sparseness of the existing information about public perceptions may lead to political 
(or business) decisions that wrongly assume that the public does not care. 
 
An admittedly simplistic interpretation of the perception studies points to the existence of two 
scales of importance in the judgement of farm animal cloning. These scales reflect judge-
ments of perceived usefulness and need; and risk and ethical or moral problems. Firstly, the 
types of organism involved in genetic manipulations seem to be on a scale, with humans be-
ing the most controversial, followed by animals, and then plants, and then micro-organisms 
as the least controversial. Areas of application make up a second scale, with medical uses at 
the least controversial end, food-related uses at the other, problematic end, and other applica-
tions occupying the space in-between. 
 
On the first of these scales, cloning sits towards the controversial end, since its object is ani-
mals. On the second scale the position depends on the purpose and application of the cloning 
being considered. Taking both scales into consideration, one would expect to find farm ani-
mal cloning in food production to be controversial in all respects. Such applications can be 
expected to be met with considerable public resistance, since they combine the controversial 
issue of GM animals and GM foods. On the other hand, however, with applications of clon-
ing for medical purposes, public judgement is much less predictable, since it largely will de-
pend on the existence of alternatives, and on perceived usefulness. Here it can be anticipated 
that applications that can be categorised as more efficient replacements of traditional tech-
nologies to produce medicine will largely will be rejected; whereas applications that repre-
sent an opportunity to produce a new medicine or novel type of therapy will greeted more 
positively. 
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